About Regenera

helping patients regain what was lost

At Regenera, we aspire to change the devastating inevitability of long-term damage to the central nervous system, bringing light to patients where there is darkness and despair today. Our lead drug candidate has the potential to restore neural function in a wide range of neurological and neurodegenerative disorders. Our dedicated team made up of highly experienced industry veterans is working tirelessly and meticulously to achieve this goal.

Lead team

    • Jordan Rubinson, MS, MBA , CEO

      Mr. Rubinson has worked for more than 20 years in the pharmaceutical industry with large pharma companies like Pfizer, GlaxoSmithKline, and Aventis. More recently Mr. Rubinson worked in early stage companies as chief commercial officer for Champions Oncology, where he grew sales 30% annually to $20M and brought the company to profitability. Just prior, Mr. Rubinson was the CEO of Polyheal Ltd, which was sold to TEVA at a $90M valuation. While in pharma, Mr. Rubinson worked at Pfizer as the marketing director for Israel. At GSK in U.S. marketing, he managed assets of over $300M in annual sales, brought to market several category-leading vaccines, and earned the company’s Frost and Sullivan Market Engineering Excellence Award. He also worked at GSK France, managing a large field force division of over 100 employees. While at Aventis, Mr. Rubinson had assignments in France, Canada and the U.S. Mr. Rubinson holds an engineering degree from Columbia University and an MBA from MIT’s Sloan School of Management.

      Jordan Rubinson, MS, MBA
    • Konstantin Adamsky, PhD , VP Operations

      Dr. Adamsky is the co-founder and former director of Targia Pharmaceuticals. He also served as project manager for Compugen, where he was responsible for designing, planning and managing new projects. Dr. Adamsky was an assistant staff scientist at the Weizmann Institute’s Department of Molecular Cell Biology and a staff scientist at Sheba Medical Center. Dr. Adamsky completed his PhD at the Weizmann Institute of Science (Israel).

    • Zadik Hazan, MD, MSc Immunology , Director R&D

      Dr. Hazan, an inventor of the product and the processes that form Regenera’s IP portfolio, has founded several pharmaceutical and medical device start-up companies. He is also recognized for his development of phantoms for ultrasound delivery, a method to prevent bacterial biofilm formation, and a treatment for irritable bowel syndrome using hypericin. Dr. Hazan received his medical degree from the University of Bologne, Italy and a master’s degree in Immunology and Medical Microbiology from the London School of Hygiene and Tropical Medicine.

    • Sharon Falach-Kovalsky , CFO

      Ms. Kovalsky is the CEO of BAMOT financial investments and CFO of EDM Energy Investments. Before joining BAMOT, she served as vice CFO at the Ashdod refinery and at the Burger Ranch food chain, and held senior management positions at Pasgas Ltd. Ms. Kovalsky holds a bachelor’s degree in Economics and an MBA from the University of Haifa.

    • André Lucassen, PhD , Senior Director CMC & IP

      Dr. Lucassen served as a senior chemist at Novotyr Ltd. and product development manager at Infigo Diagnostics Ltd. Dr. Lucassen was also a scientific adviser for Webb & Associates, patent attorneys. As a postdoctoral research associate, he worked with Dr. van der Boom and Prof. Abraham Shanzer, both at the Weizmann Institute’s Department of Organic Chemistry (Israel). Dr. Lucassen completed his PhD with Prof. Zwanenburg at the University of Nijmegen’s Department of Organic Chemistry (The Netherlands).

    • Marius Nacht , Chairman of the Board

      Mr. Nacht, together with Dr. Yair Schindel, founded aMoon Fund, a $140M healthcare & life science investment fund. He has over 10 years of experience in the biotech area, both as a co-founder of companies and as an investor. Mr. Nacht is also the co-founder of cyber security Check Point Software Technologies. He is the non-executive chairman of the board since September 2015 and served as its vice chairman from 2001 to September 2015. Mr. Nacht earned a B.S. (cum laude) in Physics and Mathematics from the Hebrew University of Jerusalem in 1983, and an M.S. in Electrical Engineering and Communication Systems from Tel Aviv University in 1987.

    • Yitzhak Peterburg, M.D., PhD, MSc. , Board Member

      Dr. Peterburg served as interim president and chief executive officer of Teva since February 2017, after serving as chairman of the board of directors since January 1, 2015. Prof. Peterburg rejoined Teva’s Board of Directors in 2012. He was Teva’s group vice president—Global Branded Products, in charge of innovative drugs, R&D and pipeline asset management from 2010–2011, after serving on Teva’s Board of Directors from 2009–2010. Previously, he served as president and CEO of Cellcom Israel Ltd. from 2003 to 2005 and as director general of Clalit Health Services, the leading healthcare provider in Israel, from 1997 to 2002. He is a professor at the School of Business, Ben-Gurion University, and served as chairman of the board of Applisonix Ltd. from 2007 until 2010. Prof. Peterburg currently serves as a director on the board of Rosetta Genomics Ltd. Prof. Peterburg received his M.D. from Hadassah Medical School in 1977 and is board-certified in Pediatrics and Health Services Management. Prof. Peterburg received a doctoral degree in Health Administration from Columbia University in 1987 and an M.Sc. degree in Information Systems from the London School of Economics in 1990.

    • Zadik Hazan, MD, MSc Immunology , Board Member

      Dr. Hazan serves as the chief scientific officer of the company. Dr. Hazan is an inventor of the product RPh and the processes that form Regenera’s IP portfolio. He has founded several pharmaceutical and medical device start-up companies. He is also recognized for his development of phantoms for ultrasound delivery, a method to prevent bacterial biofilm formation, and a treatment for irritable bowel syndrome using hypericin. Dr. Hazan received his medical degree from the University of Bologne, Italy and a master’s degree in Immunology and Medical Microbiology from the London School of Hygiene and Tropical Medicine.

    • Shlomo Shalev , Board Member

      Shlomo Shalev serves as chairman of the board of Intercure Ltd, is an investor in Regenera, and is CEO of GFC Capital, an investment company publicly traded in TASE. From 2007 to 2013 Mr. Shalev led several companies in turn-around and growth situations, including as chairman of the board of Micronet, a company publicly traded in TASE. Prior to that, Mr. Shalev served as SVP Investments at Ampal, a diversified holding company. Mr. Shalev was involved in and led a number of transactions including M&As and IPOs. Between 1994 and 1998, Mr. Shalev served as Israel’s Economic Consul to the U.S. Northwestern Region. Mr. Shalev has a BA in economics from Ben Gurion University and MBA from University of S.F., CA.

    • Sharon Falach-Kovalsky , Board Member

      Ms. Kovalsky is the CEO of BAMOT financial investments and CFO of EDM Energy Investments. Before joining BAMOT, she served as vice CFO at the Ashdod refinery and at the Burger Ranch food chain, and held senior management positions at Pasgas Ltd. Ms. Kovalsky holds a bachelor’s degree in Economics and an MBA from the University of Haifa.